Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort
The evidence regarding effects of statins on exacerbation risk in COPD remains controversial. Previous studies often excluded patients with cardiovascular comorbidities despite their high prevalence in COPD and role for exacerbations. Based on the cardioprotective properties of statins, we hypothesi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 May 2024
|
| In: |
Respiratory research
Year: 2024, Volume: 25, Pages: 1-12 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-024-02822-1 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12931-024-02822-1 |
| Author Notes: | N. Frantzi, X.P. Nguyen, C. Herr, P. Alter, S. Söhler, D. Soriano, H. Watz, B. Waschki, F. Trinkmann, M. Eichenlaub, F.C. Trudzinski, J.D. Michels-Zetsche, A. Omlor, F. Seiler, I. Moneke, F. Biertz, G. Rohde, D. Stolz, T. Welte, H.U. Kauczor, K. Kahnert, R.A. Jörres, C.F. Vogelmeier, R. Bals, S. Fähndrich and on behalf of the German COSYCONET Cohort |
| Summary: | The evidence regarding effects of statins on exacerbation risk in COPD remains controversial. Previous studies often excluded patients with cardiovascular comorbidities despite their high prevalence in COPD and role for exacerbations. Based on the cardioprotective properties of statins, we hypothesised that statins may reduce the risk of exacerbations especially in patients with cardiovascular comorbidities. |
|---|---|
| Item Description: | Gesehen am 25.11.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-024-02822-1 |